CGT and Muzza,
I did not mean the antibiotic program is not good. But if we consider the company as a whole, stratigically, it was not a good time for Biota to expand its business by acquisition. Biota should have focused on its flu antiviral programs, RSV and HCV programs only.
We do not know how much cash has been burnt into the two acquired businesses during the last few years after acquisition. Biota does not lack promising pipelines. It is the valuable cash reserve that is the biggist problem that worries us here. We continue to hear good news from Biota's product development and trials, but do not see the share price react accordingly. Why? IMO, it is mainly due to the cash reserve problem, Otherwise, those big players would have rushed to take up a position in BOTA.
Moreover, we should also ask the question "why those big pharmes did not look at the two businesses when Biota did?".
More things are pointing to my belief that Biota is runned and planned to do a big cap raising before Lani hits the US market.
just my thoughts.
Add to My Watchlist
What is My Watchlist?